Drug Profile
AZD 8165
Alternative Names: AZD8165Latest Information Update: 04 Feb 2014
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 01 Sep 2010 Discontinued - Phase-I for Thrombosis in USA (PO)
- 01 Jun 2010 Phase-I clinical trials in Thrombosis in USA (PO)